Concerning the ALDF-IDSA relationship

1. There are 6 overlapping members between the 14 IDSA Lyme Panel and

9 ALDF Scientific Advisor Clinicians: Wormser, Nadelman, Fish, Shapiro, Steere, Sigal (IDSA reviewer)

2. A grad student, Elizabeth Lutzker, in Durland Fish's Yale Lab

(which is funded by a CDC grant) is involved with the ALDF website.

"She is also analyzing the need for Lyme disease educated

physicians for the ALDF (American Lyme Disease Foundation)"

http://info.med.yale.edu/eph/vectorbio/fish/Templates/Elizabeth%

20Lutzker.htm

3. The CDC and Durland Fish earn money off the tick prevention device promoted on the ALDF website:

"Montvale-based Bayer Environmental Science launched Maxforce under a CDC license last year and now sells it in 18 states and Washington, D.C. Prices run from a few hundred dollars to $1,000 per year, depending on property size and amount of brush.The 4-Poster device was licensed to the American Lyme Disease Foundation, which gets a small royalty on sales, and to manufacturer C.R. Daniels Inc. of Ellicott City, Md."

Bakken on the IDSA panel has received speaker fees from Bayer.

4. Some ALDF board members stand to profit from drugs used to treat

late stage "post-Lyme syndrome":

Jeffrey Black: Executive VP, CFO, and founder of Endo Pharmaceuticals

Holdings Inc. (joined in 1997, retired 2006), Formerly @ Delloitt,

Endo specializes in pain management drugs. This company financially

benefits from drugs that address chronic Lyme symptoms, such as

migraines, tendonitis, low back pain, and chronic neurological pain.

John Geron: Managing Director, Navigant Consulting, New York, NY.

Specializes in helping pharmaceutical companies with litigation,

gov’t investigations, and strategies for marketing drugs to

physicians. Having control of the ALDF website has the potential to

be attractive to clients who sell Lyme-related drugs, vaccines, and

test kits. He wrote: “Putting Pharma Marketing ROI Strategies to

Work” Studies how to manipulate physicians to motivate them to

prescribe pharmaceutical companies drugs.

http://www.navigantconsulting.com/A559B1/navigantnew.nsf/fCNTDspRead?

OpenForm&Cat1=LA6&Cat2=LB6

Sponsors conferences on "Strategies for Responding to Insurance

Industry Investigations" where they “shared tips for dealing with

probes and lawsuits.”

http://www.businessinsurance.com/cgi-bin/industryFocus.pl?

articleId=16373&issueDate=2005-03-20

Mr. David G. Nichols, Jr., JD: Partner, Life Sciences Transactions,

Morgan, Lewis & Bockus As head of the Life Sciences Transactions

group, he specializes in legal work around commercialization of new

products and represents academic institutions that are out-licensing

technology. Life Sciences practice focuses on all important areas,

from transactions and litigation to regulatory approvals and

compliance and protection of intellectual property, as well as key

supporting capabilities, including FDA/healthcare, patents and patent

litigation.

Morgan Lewis clients involved in health insurance or Lyme-related

products include:

Cigna (IP, ERISA Medical denial of coverage cases)

http://www.law.com/special/professionals/protect_ip_chart.html

WellPoint Health Networks Inc. (Litigation)

AdvancePCS Inc. (IP)

http://www.morganlewis.com/pubs/NationalLawJournal_WhoRepCorpAmerica.pdf

American Business Meda: Legal Council, spokesperson on managing

business healthcare costs.

https://www.americanbusinessmedia.com/images/abm/pdfs/committees/

minutes/HRCommittee7-8.pdf

Sanofi-Aventis in the restructuring of its Actonel® collaboration

with Procter & Gamble

Aventis in its up to $485 million collaboration with Regeneron to

develop and commercialize VEGF-Trap products, and related equity

investment Bristol-Myers Squibb in the outsourcing of certain administrative and clinical functions

Adolor in its worldwide development and commercialization

collaboration for Entereg® with GlaxoSmithKline Pharmasset

Aventis in its inhaled insulin strategic alliance with Pfizer and

related collaboration and licensing arrangements with Nektar Therapeutics Robert A. Proctor III: Managing Partner, Oak Hill Consultants LLC Bedford Corners, NY. Board of the Lounsberry Society of Northern Westchester Hospital.

Head of an executive search firm. Among his major personal client is

Bayer AG (purchased from Aventis ES in 2001), which has several Lyme

related commercial products, including Maxforce Tick Management

System for killing Lyme within mice and chipmunks, as well as tick

collars for dogs. (The CDC and Aventis hold this patent.)

http://www.nj.com/specialprojects/index.ssf?/specialprojects/lyme/

0513lyme.html

Oak Hill works with these firms with vested interests in reducing the

costs of long-term Lyme disease treatments: Aetna, Prudential, MetLife

Kris Newby

Senior Producer

UNDER OUR SKIN: An infectious film about microbes, money, and medicine